LOGIN  |  REGISTER
Viking Therapeutics

NEXGEL to Report Second Quarter 2023 Financial Results on August 14th

August 02, 2023 | Last Trade: US$2.85 0.17 -5.63
  • Management will host a conference call at 4:30 P.M. ET on the same day

LANGHORNE, Pa., Aug. 02, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter ended June 30, 2023, after the market closes on August 14, 2023.

Following the release of its financial and operating results, the Company will host a conference call at 4:30 P.M. ET on August 14, 2023. The conference call will be webcast live and can be accessed by registering on the Events and Presentations portion of NEXGEL’s Investor Relations website. The webcast will be archived for approximately 90 days.

NEXGEL Second Quarter 2023 Financial Results Conference Call

Date: August 14, 2023

Time: 4:30 P.M. ET

Live Call: +1-877-300-8521 (U.S. Toll Free) or +1-412-317-6026 (International)

Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1627569&tp_key=69c361dd6d

For interested individuals unable to join the conference call, a replay will be available through August 28, 2023, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 10181557. An archived version of the webcast will also be available on NEXGEL’s Investor Relations site: https://ir.nexgel.com/.

About NEXGEL, INC.

NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contacts:
Kelly Knobeck
Director of Consumer Products
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page